Sharon L Walsh Selected Research

Miosis

9/2021	Relative potency of intravenous oxymorphone compared to other µ opioid agonists in humans - pilot study outcomes.
11/2019	Cannabinoid modulation of opioid analgesia and subjective drug effects in healthy humans.
1/2017	Effects of Short-Term Oxycodone Maintenance on Experimental Pain Responses in Physically Dependent Opioid Abusers.
5/2016	Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers.
1/2016	Pharmacodynamic effects of oral oxymorphone: abuse liability, analgesic profile and direct physiologic effects in humans.
12/2015	Safety of oral dronabinol during opioid withdrawal in humans.
11/2013	Efficacy of extended-release tramadol for treatment of prescription opioid withdrawal: a two-phase randomized controlled trial.
10/2012	Pharmacodynamic profile of tramadol in humans: influence of naltrexone pretreatment.
10/2010	Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies.
12/2008	The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sharon L Walsh Research Topics

Disease

35	Opioid-Related Disorders (Opiate Addiction) 01/2022 - 01/2002
11	Miosis 09/2021 - 08/2004
11	Pain (Aches) 01/2021 - 05/2010
8	Opiate Overdose 07/2022 - 11/2015
7	Substance-Related Disorders (Drug Abuse) 01/2021 - 12/2009
6	Respiratory Insufficiency (Respiratory Failure) 09/2021 - 12/2008
5	Substance Withdrawal Syndrome (Withdrawal Symptoms) 01/2020 - 05/2002
5	Cocaine-Related Disorders (Cocaine Addiction) 06/2013 - 04/2003
4	Infections 01/2021 - 01/2018
3	Drug Overdose 01/2023 - 01/2020
3	Mental Disorders (Mental Disorder) 01/2021 - 05/2011
3	Chronic Pain 01/2020 - 11/2015
2	Hepatitis C 01/2021 - 01/2018
2	Tobacco Use Disorder (Nicotine Dependence) 01/2020 - 06/2014
2	Rhinorrhea 11/2013 - 04/2003
2	Poisoning 07/2013 - 07/2009
2	Alcoholism (Alcohol Abuse) 05/2010 - 12/2009
2	Heroin Dependence (Heroin Abuse) 10/2005 - 05/2002
1	COVID-19 01/2022
1	Hepatitis 01/2021
1	Nervous System Diseases (Neurological Disorders) 01/2021
1	Inflammation (Inflammations) 01/2021
1	Psychotic Disorders (Schizoaffective Disorder) 01/2020
1	Drug Misuse 01/2020
1	Hallucinations (Hallucination) 01/2020
1	Ataxia (Dyssynergia) 01/2020
1	Cancer Pain 11/2019
1	Nausea 12/2018
1	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 12/2018
1	Neoplasms (Cancer) 03/2017
1	Epilepsy (Aura) 03/2017
1	Arthritis (Polyarthritis) 01/2017
1	Acute Pain 01/2017
1	Opium Dependence 01/2017
1	Hypotension (Low Blood Pressure) 01/2017
1	Crohn Disease (Crohn's Disease) 01/2017
1	Tachycardia (Tachyarrhythmias) 07/2016
1	Sinus Tachycardia 12/2015
1	Sleep Initiation and Maintenance Disorders (Insomnia) 11/2013
1	Sneezing 11/2013
1	Mydriasis 10/2012
1	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 05/2011
1	Antisocial Personality Disorder (Antisocial Personality) 05/2011
1	Exotropia (Exophoria) 12/2008

Drug/Important Bio-Agent (IBA)

34	Opioid Analgesics (Opioids)IBA 01/2023 - 01/2002
22	Buprenorphine (Subutex)FDA LinkGeneric 01/2022 - 01/2002
14	Pharmaceutical PreparationsIBA 01/2023 - 07/2009
7	Cocaine (Cocaine HCl)IBA 01/2023 - 04/2003
7	Oxycodone (Oxycontin)FDA LinkGeneric 07/2021 - 06/2012
7	Analgesics (Analgesic Drugs)IBA 01/2020 - 06/2012
6	Naloxone (Narcan)FDA LinkGeneric 07/2022 - 04/2003
3	Fentanyl (Sublimaze)FDA LinkGeneric 01/2023 - 01/2018
3	Heroin (Diamorphine)IBA 01/2023 - 05/2002
3	Anti-Bacterial Agents (Antibiotics)IBA 01/2020 - 01/2018
3	Dronabinol (THC)FDA LinkGeneric 11/2019 - 12/2015
3	mu Opioid Receptors (mu Opioid Receptor)IBA 03/2019 - 08/2010
3	Opiate AlkaloidsIBA 06/2012 - 05/2002
2	Oxymorphone (Numorphan)FDA LinkGeneric 09/2021 - 01/2016
2	Naltrexone (ReVia)FDA LinkGeneric 02/2021 - 10/2012
2	Therapeutic UsesIBA 01/2021 - 03/2017
2	CannabinoidsIBA 01/2020 - 07/2016
2	Gabapentin (Neurontin)FDA LinkGeneric 01/2020 - 01/2016
2	Hydromorphone (Dilaudid)FDA LinkGeneric 01/2017 - 10/2012
2	Clonidine (ST 155)FDA LinkGeneric 01/2017 - 04/2003
2	lofexidineIBA 01/2017 - 04/2003
2	Tramadol (K315)FDA LinkGeneric 11/2013 - 10/2012
2	Methadone (Dolophine)FDA LinkGeneric 10/2005 - 05/2002
1	Controlled SubstancesIBA 01/2022
1	hydroxide ionIBA 11/2021
1	velpatasvirIBA 01/2021
1	SofosbuvirIBA 01/2021
1	Pregabalin (Lyrica)FDA Link 01/2020
1	Duloxetine Hydrochloride (Cymbalta)FDA Link 01/2020
1	kappa Opioid Receptors (kappa Opioid Receptor)IBA 01/2020
1	A 17 (A-17)IBA 01/2020
1	AticaprantIBA 01/2020
1	Nicotine FDA Link 01/2020
1	Cannabinoid Receptor AgonistsIBA 11/2019
1	Methylphenidate (Ritalin)FDA LinkGeneric 12/2018
1	Lobeline (Smokeless)IBA 12/2018
1	Illicit Drugs (Recreational Drugs)IBA 01/2018
1	Delayed-Action PreparationsIBA 01/2018
1	CB1 Cannabinoid Receptor (CB1 Receptor)IBA 07/2016
1	Aripiprazole (Abilify)FDA Link 06/2014
1	Prescription DrugsIBA 07/2013
1	Atomoxetine Hydrochloride (Strattera)FDA LinkGeneric 06/2013
1	2- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA 06/2012
1	Naloxone Drug Combination Buprenorphine FDA Link 08/2011
1	Opioid Receptors (Opioid Receptor)IBA 05/2010
1	Ketoconazole (Nizoral)FDA LinkGeneric 08/2004
1	Methadyl Acetate (LAAM)FDA Link 08/2004
1	Capsules (Microcapsules)IBA 01/2004
1	PolymersIBA 01/2004

Therapy/Procedure

6	Drug Therapy (Chemotherapy) 01/2018 - 10/2005
3	Therapeutics 01/2020 - 03/2004
3	Self Administration (Administration, Self) 01/2020 - 01/2010
2	Continuity of Patient Care 02/2021 - 12/2020
2	Analgesia 11/2019 - 01/2017
1	Length of Stay 01/2020
1	Drug Tapering 12/2015